MDMA

The Food and Drug Administration (FDA) this week declined to approve the use of MDMA — popularly known as Ecstasy or Molly — for MDMA-assisted therapy for treating PTSD, disappointing many Americans who suffer with intractable mental health conditions and had pinned their hopes on the treatment....

A panel of advisors to the Food and Drug Administration (FDA) rejected MDMA as a treatment for post-traumatic stress disorder (PTSD) on Tuesday, citing a lack of evidence that the benefits would outweigh the risks of introducing the psychedelic treatment to patients. Most stocks in the psychedelic...

Three Key Takeaways: FDA Nods to MDMA Therapy Application: The FDA has accepted Lykos Therapeutics’ application for MDMA-assisted therapy for PTSD, marking a significant step in recognizing psychedelic therapies’ medical potential. A Milestone in Psychedelic Research: This development...

In a groundbreaking move, the U.S. Department of Veterans Affairs (VA) is launching new studies on using psychedelic compounds to treat post-traumatic stress disorder (PTSD) and depression among military veterans. This marks a significant shift for the VA, representing the first such research since...

A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Public Benefit Corporation has secured over $100 million in a Series A private stock sale. The funds will support the final stages of its application for...

Studies and reports from the U.S. Department of Veterans Affairs (VA) and other research publications suggest that an estimated 20-30% of U.S. veterans may experience some form of mental health disorder, with depression and anxiety ranking high amongst conditions.  According the New England...

In this episode of The Dales Report, we’re sitting down with Numinus Wellness CEO Payton Nyquvest for a psychedelic exclusive. Our topic of conversation with Payton today steers into the recent FDA warning and the dynamic world of off-label markets for new compounds. First up: The FDA made...

We’re back with another TDR Psychedelic Exclusive. In this latest episode, Cody Shandraw, Founder and Managing Partner of Ambria Capital, joins us to talk about MAPS, MDMA, the Food and Drug Administration, and more. Ambria Capital is an investment firm focused on companies in...

From 1 July this year, medicines containing the psychedelic substances psilocybin and MDMA (3,4-methylenedioxy-methamphetamine) can be prescribed by specifically authorised psychiatrists for the treatment of certain mental health conditions. Huge news tonight coming out of Australia. The...

In this week’s Trade To Black Podcast, TDR Founder Shadd Dales, lead financial writer Benjamin A. Smith and TDR contributor Anthony Varrell give their macro outlook in the cannabis, crypto and psychedelic sectors—the latter boosted early year on the promise of regulatory approval of...

The Connecticut House of Representatives approved a budget bill that includes provisions to grant certain patients access to MDMA-assisted or psilocybin-assisted therapy, reported Marijuana Moment. The bill would create psychedelic treatment centers in the state as part of an expanded access...

What Happened: According to the Multidisciplinary Association of Psychedelic Studies (MAPS), a non-profit organization, the FDA is close to greenlighting MDMA as a treatment for PTSD. MAPS reported positive results from a phase-3 trial testing the efficacy of MDMA-assisted...

Nick Watchorn had suffered for most of his adult life from severe post-traumatic stress disorder (PTSD) before he sought psychedelic treatments to deal with his chronic condition. He credits those psychoactive sessions, and particularly the work he did afterwards in a process known as integration...

Venture capitalist and businessman Stephen Jurvetson is joining an expanding group of prominent investors who are backing research into psychedelic ventures. Last week, Jurvetson spoke at the New York City conference “Horizons: Perspectives on Psychedelics” on the...

Psychedelic therapy company, Cybin Inc. (NEO: CYBN) (NYSE: CYBN), recently announced it was awarded a grant for the first psychedelic treatment clinic at New York City’s Lenox Hill Hospital with which it will provide care to marginalized and underserved communities on Manhattan...